Cordyceps Sunshine Biotech Holdings (RAJAF) Liabilities and Shareholders Equity (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $4.7 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 0.73% year-over-year to $4.7 million; the TTM figure through Dec 2025 stood at $14.4 million (up 21.49% YoY), while the FY2025 annual figure was $4.7 million, up 0.73% from the prior year.
• Liabilities and Shareholders Equity was $4.7 million for Q4 2025 at Cordyceps Sunshine Biotech Holdings, up from $4.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.7 million in Q4 2025 to a low of $1.8 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $3.3 million across 5 years, with a median of $3.3 million in 2021.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity sank 35.49% in 2022, then soared 59.24% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.3 million in 2021, then sank by 35.49% to $2.1 million in 2022, then surged by 59.24% to $3.4 million in 2023, then soared by 37.95% to $4.6 million in 2024, then climbed by 0.73% to $4.7 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $4.7 million (Q4 2025), $4.6 million (Q4 2024), and $3.4 million (Q4 2023), per Business Quant data.